pyronaridine: Clinical Trials

5 trials of pyronaridine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 suspended, 1 unknown. 5 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 25Completed 3, Suspended 1, Unknown 1
Phase 31Completed 1

Follow pyronaridine: new trials by email Literature Review of pyronaridine trials Research Report on pyronaridine

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pyronaridine in Acute Myeloid Leukemia (AML)
Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Phase 2SuspendedArmaceutica, Inc.2002028-02-212026-10-19
Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)
M5717 60 mg, Pyronaridine, Atovaquone-Proguanil - Malaria Infection
Phase 2CompletedMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany1922023-11-282026-02-06
Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)
M5717 330 mg, M5717 500 mg, M5717 660 mg - Acute Malaria
Phase 2CompletedMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany382023-03-292025-08-27
Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission
Pyronaridine Tetraphosphate/Artesunate, Dihydroartemisinin/Piperaquine, Primaquine Diphosphate - Malaria,Falciparum
Phase 2 / Phase 3CompletedLondon School of Hygiene and Tropical Medicine1002019-09-122020-01-30
Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections
Pyronaridine tetraphosphate 180mg:artesunate 60mg - Malaria,Falciparum
Phase 2UnknownShin Poong Pharmaceutical Co. Ltd.3002018-10-032019-09-30

Conditions studied

Malaria, Falciparum (4)  ·  Acute malaria (1)  ·  Asymptomatic Infections (1)  ·  Leukemia (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Malaria (1)  ·  Neoplasms (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)

Sponsors

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (2)  ·  Armaceutica, Inc. (1)  ·  London School of Hygiene and Tropical Medicine (1)  ·  Shin Poong Pharmaceutical Co. Ltd. (1)

Countries

Burkina Faso (2)  ·  The Gambia (2)  ·  Zambia (2)  ·  Gabon (1)  ·  Kenya (1)  ·  Mali (1)  ·  Mozambique (1)  ·  Netherlands (1)  ·  Senegal (1)  ·  Uganda (1)

Top investigators

Jang Sik Shin (1)  ·  Renato J Aguilera, PhD (1)

Results publications

PMID 33983371, PMID 35028628, PMID 42462745